0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Molecular Markers for Malignancy in Adrenocortical Tumors

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Little is known about the pathophysiology of sporadic adrenocortical tumors. Benign and malignant adrenocortical tumors are often difficult to distinguish by conventional histology. We tested 38 adrenocortical tumors (23 benign and 15 malignant) for loss of heterozygosity (LOH) at 17pl3 and abnormalities in the 11p15 region (uniparental disomy, UPD, and overexpression of the IGF II gene). We showed that 17p13 LOH, 11p15 UPD and overexpression of the IGF II gene are frequent in adrenocortical tumors, occurring in 40% of them. These genetic changes are associated with the malignant phenotype and thus could be used for diagnostic evaluation of adrenocortical tumors.

          Related collections

          Author and article information

          Journal
          HRE
          Horm Res Paediatr
          10.1159/issn.1663-2818
          Hormone Research in Paediatrics
          S. Karger AG
          978-3-8055-6504-2
          978-3-318-01928-5
          1663-2818
          1663-2826
          1997
          1997
          09 December 2008
          : 47
          : 4-6
          : 269-272
          Affiliations
          Laboratoire d’Explorations Fonctionnelles Endocriniennes, Hôpital Trousseau, Réseau INSERM Comète, No. 493015, Paris, France
          Article
          185475 Horm Res 1997;47:269–272
          10.1159/000185475
          9167963
          © 1997 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 4
          Categories
          Recent Progress on the Molecular Aspects of Endocrine Tumors: Clinical Implications

          Comments

          Comment on this article